Current Utilization of Mast Cell Stabilizers for Preemptive Treatment of NF1 Neurofibromas
Journal Title: Neuro – Open Journal - Year 2015, Vol 2, Issue 2
Abstract
The morbidity and mortality of Neurofibromatosis type I (NF1) are both largely related to the person’s neurofibroma burden. That burden can presently be minimized by mast cell stabilizers, with ketotifen as the one most frequently considered for NF1 patients in the published literature. Here, I review pertinent clinical and research publications to 1) document the rationale for using mast cell blockers in NF1, 2) consider the NF1 clinical impact of mast cell blockers, 3) document the relative safety and very modest expense of (at least some) mast cell blockers, and 4) suggest that the data are sufficiently robust to support the regular, if not routine use of mast cell blockers to treat NF1, particularly in children, while the NF1 neurofibroma burden is the least it will be. The rationale for these salutary results have been established by histopathology, Nf1+/- mouse models, a series of open-label and double-blind protocols, compelling case reports and a series of patients who have afforded their own self-determined mast cell stabilizer treatment (most often ketotifen). In addition, in the intervening 20-plus years since the first formal protocol publications, the positive treatment results have never been refuted or contradicted. The results of the mast-cell-stabilizing treatment are designed to keep the NF1 neurofibroma burden and its consequences at their minimums, in effect preempting NF1 neurofibroma initiation and progression as much as possible.
Authors and Affiliations
Vincent M. Riccardi
Keywords
Related Articles
- EP ID EP553088
- DOI 10.17140/NOJ2-115
- Views 110
- Downloads 0
Neuromodulation in the Treatment of Migraine: Progress in Nerve Stimulation
Migraine is a type of primary headache disorder that can become chronic and disabling. The exact pathomechanism of migraine is not known very well and its treatment is also difficult in some cases. There are several medi...
Mobile Stroke Unit (MSU): The Future of Acute Stroke Treatment?
Time is the key factor in brain survivability in acute stroke treatment.1The therapeutic effects of intravenous recombinant tissue Plasminogen Activator (IV rtPA) are highly dependent on time.1-3 Stroke patients presenti...
An Unusual Intracranial Inflammatory Process of Unknown Origin
We present an unusual case of steroid responsive inflammatory condition, involving sellar suprasellar region with further ependymal lesions. This is complicated by previous surgery due to pituitary adenoma, not thought t...
Multiplicity as a Factor in Understanding NF1
The NF1 locus on the long arm of chromosome 17 is a very special gene in the human genome. In terms of multiplicity, there are five pseudogenes on five other chromosomes; it influences the formation and/or behavior of ma...
New Criteria Reduce Inter-Observer Variability in Chronic Cerebrospinal Venous Insufficiency: A Case Control Study
Background: The pathophysiological mechanism defined “chronic cerebrospinal venous insufficiency” (CCSVI) diagnosed using Zamboni criteria has raised a heated debate about possible correlations with several neurological...